S&P 500
5.307,01 -14,40 (-0,27%) Nasdaq
16.801,54 -31,08 (-0,18%) NIKKEI 225
38.617,10 -329,83 (-0,85%) Dólar/Euro
1,0828 +0,0001 (+0,01%) Petróleo Brent
81,48 -0,42 (-0,51%) Bitcoin EUR
63.765,93 -1.099,38 (-1,69%)
BeiGene, Ltd. (BGNE)
Después del cierre:
BeiGene, Ltd.
94 Solaris Avenue
Camana Bay KY1-1108
Cayman Islands
345-949-4123
https://www.beigene.com
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 10.000
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. John V. Oyler | Co-Founder, Executive Chairman & CEO | 2,43M | N/A | 1968 |
| Dr. Xiaobin Wu Ph.D. | President & COO | 1,7M | N/A | 1962 |
| Dr. Xiaodong Wang Ph.D. | Co-Chairman of Scientific Advisory Board & Non-Executive Director and Co-Founder | 4,42M | N/A | 1963 |
| Ms. Julia Wang | CFO & Principal Financial Officer | 1,07M | N/A | 1971 |
| Mr. Chan Lee | General Counsel & Senior VP | 1,01M | N/A | 1968 |
| Mr. Wang Lai Ph.D. | Global Head of R&D | 1,12M | N/A | 1977 |
| Mr. Titus B. Ball | VP & Chief Accounting Officer | N/A | N/A | 1973 |
| Ms. Liza Heapes | Head of Investor Relations | N/A | N/A | N/A |
| Mr. Yang Ji | Chief Compliance Officer | N/A | N/A | N/A |
| Dr. Yan Qi | Senior VP & Head of Public Affairs - Greater China | N/A | N/A | N/A |
Descripción
BeiGene Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. Its commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and PARTRUVIX, a selective small molecule inhibitor of PARP1 and PARP2 enzymes that is being evaluated as a monotherapy and in combinations for the treatment of various solid tumors. The company's clinical stage products comprise BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK-targeting chimeric degradation activation compound active against wild-type and mutant BTK; BGB-10188; BGB-21447, a Bcl-2 inhibitor; Ociperlimab (BGB-A1217), a TIGIT inhibitor; Zanidatamab, a bispecific HER2-targeted antibody; Surzebiclimab (BGB-A425), a TIM-3 inhibitor; BGB-A445, an OX40 agonist antibody; BGB-15025, a small molecule inhibitor of HPK1; BGB-24714, a SMAC mimetic; BGB-26808, a HPK-1 inhibitor; Lifirafenib and BGB-3245 that are inhibitors of RAF; BGB-30813; BGB-A3055, an anti-CCR8 antibody; and BGB-43395, a CDK-4 inhibitor. It also has various preclinical programs. The company has license agreements with Ensem Therapeutics, Inc.; Shandong Luye Pharmaceutical Co., Ltd.; Shoreline Biosciences, Inc.; Nanjing Leads Biolabs, Inc.; EUSA Pharma; Assembly Biosciences, Inc.; Bio-Thera Solutions, Ltd.; Amgen Inc.; and Beijing Novartis Pharma Co., Ltd. BeiGene Ltd. was incorporated in 2010 and is based in Camana Bay, the Cayman Islands.
Gobierno corporativo
El ISS Governance QualityScore de BeiGene, Ltd., a día 1 de mayo de 2024, es 8. Las puntuaciones base son Auditoría: 9; Tablero: 5; Derechos de los accionistas: 6; Compensación: 10.
